Shooting for early OK, Sarepta lays out promising 3-year data on Duchenne drug

John Carroll FierceBiotech News

Insurers balk at pricey generic version of ancient GSK heart drug

Arlene Weintraub The heart drug digoxin–a generic version of GlaxoSmithKline's Lanoxin–used to cost just pennies a pill, making it a prescription that insurance companies ...

NIH sickle cell partner AesRx moves up the food chain in Baxter buyout

John Carroll Having played a pioneering role collaborating with the NIH on a new drug for sickle cell disease, Newton, MA-based AesRx has moved up the food chain after completing a ...

Actavis cans 190 Forest workers while 6 execs share up to $186M in deal ‘awards’

Eric Palmer There are winners and losers in mergers, and as a general rule, executives win and at least some workers lose. That certainly is the case with Actavis and Forest Laboratories. ...

International brouhaha over AbbVie misstep highlights U.K.’s M&A rules

John Carroll Analysts generally believe that big takeovers are easier to pull off under the U.K.'s M&A guidelines. But you'd better not ignore the very specific rules of ...

Sanofi hits Lilly with more Lantus infringement charges

Carly Helfand Sanofi has already slapped Eli Lilly with one patent infringement lawsuit over its Lantus copy, effectively keeping the competitor off the market until ...

Wall Street wonders what Shire is worth

Stacy Lawrence The share prices of AbbVie and takeover target Shire keep drifting downward amid sustained uncertainty over a deal. A couple of healthcare investors we talked to feel ...

Judge tosses decade-old investor suit against Pfizer and Celebrex weeks before trial

Eric Palmer A long-running and often contentious securities lawsuit tied to Pfizer's vilified pain drugs Celebrex and Bextra was set for a September trial, ...

Sanofi ups the legal ante to block Lilly’s Lantus biosimilar

Damian Garde Sanofi has filed another lawsuit against Eli Lilly in hopes of beating back a biosimilar challenge for its top-selling insulin product, claiming its rival's in-development ...

M&A spotlight: Allergan plots cost cuts to ward off Valeant, AbbVie may have to raise Shire bid–again

Carly Helfand Allergan can't stop Valeant from attempting to round up enough support to call a special meeting, overturn its board and strike its takeover defenses. But it can make ...

Which big brands will still be bringing in the big bucks in 2020?

Emily Wasserman Best-selling drugs did well for themselves in 2013, churning out more than $ 76 billion in sales. But big-name brands could stand the test of time and help the top ...

‘Unpromising’ Allergan drug projects headed for the chopping block–report

John Carroll Allergan execs have made no secret of the fact that they've been planning to come up with a lean-and-mean game plan designed to prove to investors that they'd ...
Page 10 of 12« First...89101112
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS